COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,555 Articles (22,400 medRxiv, 8,155 bioRxiv)

Most recent first Previous |  Page 2034: Articles 20331-20340  | Next

Plasma proteomics reveals tissue-specific cell death and mediators of cell-cell interactions in severe COVID-19 patients
Filbin, M. R., Mehta, A., Schneider, A. M., Kays, K. R., Guess, J. R., Gentili, M., Fenyves, B. G., Charland, N. C., Gonye, A. L. K., Gushterova, I., Khanna, H. K., LaSalle, T. J., Lavin-Parsons, K. M., Lilley, B. M., Lodenstein, C. L., Manakongtreecheep, K., Margolin, J. D., McKaig, B. N., Rojas-Lopez, M., Russo, B. C., Sharma, N., Tantivit, J., Thomas, M. F., Gerszten, R. E., Heimberg, G. S., Hoover, P. J., Lieb, D. J., Lin, B., Ngo, D., Pelka, K., Reyes, M., Smillie, C. S., Waghray, A., Wood, T. E., Zajac, A. S., Jennings, L. J., Grundberg, I., Bhattacharyya, R. P., Parry, B. A., Villani, A.-C., Sade-Feldman, M., Hacohen, N., Goldberg, M. B.
10.1101/2020.11.02.365536 — Posted: 2020-11-03
Computational prediction of SARS-CoV-2 encoded miRNAs and their putative host targets
Verma, S., Dwivedy, A., Kumar, N., Biswal, B. K.
10.1101/2020.11.02.365049 — Posted: 2020-11-03
Modelling the active SARS-CoV-2 helicase complex as a basis for structure-based inhibitor design
Berta, D., Badaoui, M., Buigues, P. J., Martino, S. A., Pisliakov, A., Elghobashi-Meinhardt, N., Wells, G., Harris, S. A., Frezza, E., Rosta, E.
10.1101/2020.11.03.366609 — Posted: 2020-11-03
Association of Mass Gatherings and COVID-19 Hospitalization
Miron, O., Yu, K.-H., Wilf-Miron, R., Davidovitch, N.
10.1101/2020.10.27.20220707 — Posted: 2020-11-03
COVID-19 Mortality Following Mass Gatherings
Miron, O., Yu, K.-H., Wilf-Miron, R., Davidovitch, N.
10.1101/2020.10.27.20219717 — Posted: 2020-11-03
COVID-19 risk haplogroups differ between populations, deviate from Neanderthal haplotypes and compromise risk assessment in non-Europeans
Wohlers, I., Calonga-Solis, V., Jobst, J.-N., Busch, H.
10.1101/2020.11.02.365551 — Posted: 2020-11-03
Potential Opportunity Of Antisense Therapy Of COVID-19 on an in vitro model
Goryachev, A. N., Kalantarov, S. A., Severova, A. G., Goryacheva, A. S.
10.1101/2020.11.02.363598 — Posted: 2020-11-03
Antiviral activity of plant juices and green tea against SARS-CoV-2 and influenza virus in vitro
Conzelmann, C., Weil, T., Gross, R., Jungke, P., Frank, B., Eggers, M., Mueller, J. A., Muench, J.
10.1101/2020.10.30.360545 — Posted: 2020-11-03
Structure of nonstructural protein 1 from SARS-CoV-2.
Clark, L. K., Green, T. J., Petit, C. M.
10.1101/2020.11.03.366757 — Posted: 2020-11-03
Rapid development of SARS-CoV-2 receptor binding domain-conjugated nanoparticle vaccine candidate
Kang, Y.-F., Sun, C., Zhuang, Z., Yuan, R.-Y., Zheng, Q.-B., Zhou, P.-P., Li, J.-P., Chen, X.-C., Zhang, X., Yu, X.-H., Kong, X.-W., Zhu, Q.-Y., Xu, M., Zhong, N.-S., Zeng, Y.-X., Feng, G.-K., Ke, C.-W., Zhao, J.-C., Zeng, M.-S.
10.1101/2020.11.03.366138 — Posted: 2020-11-03

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).